Cullinan Therapeutics (NASDAQ:CGEM) CFO Sells $59,900.76 in Stock

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) CFO Mary Kay Fenton sold 4,398 shares of the business’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $13.62, for a total transaction of $59,900.76. Following the completion of the transaction, the chief financial officer owned 126,380 shares in the company, valued at $1,721,295.60. The trade was a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Cullinan Therapeutics Stock Performance

CGEM stock opened at $14.36 on Thursday. Cullinan Therapeutics, Inc. has a one year low of $5.68 and a one year high of $14.56. The firm has a market cap of $848.39 million, a PE ratio of -4.34 and a beta of -0.09. The firm’s 50 day moving average price is $11.50 and its 200-day moving average price is $9.31.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. HC Wainwright increased their price objective on shares of Cullinan Therapeutics from $26.00 to $27.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. BTIG Research increased their target price on Cullinan Therapeutics from $32.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, November 24th. Zacks Research cut Cullinan Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 19th. Morgan Stanley reaffirmed an “overweight” rating and issued a $30.00 target price on shares of Cullinan Therapeutics in a research report on Thursday, January 8th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Cullinan Therapeutics in a research report on Monday, December 29th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Cullinan Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $29.33.

Trending Headlines about Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

• Neutral Sentiment: Recent short-interest data for CGEM appears unreliable (reports show 0 shares and NaN change), so there’s no clear evidence of rising short interest to explain price moves — treat that data as a likely reporting glitch.
• Neutral Sentiment: Broader market weakness (e.g., a sharp pullback in Bitcoin this month) can contribute to risk-off flows in small-cap and biotech stocks, but this is an indirect factor. Bitcoin article
• Negative Sentiment: Multiple insiders sold shares on Feb. 24 — combined ~27,051 shares (~$390.6k at ~ $14.47 average). CEO Nadim Ahmed sold 13,515 shares (≈$195.6k), reducing his stake by ~3.34%. These sizable, contemporaneous sales by the CEO and other executives can be perceived negatively by the market as signal of insider profit-taking or reduced conviction. SEC filings: Ahmed filing, Sumer filing, Jones filing, Michaelson filings

Hedge Funds Weigh In On Cullinan Therapeutics

Several large investors have recently bought and sold shares of the business. Lynx1 Capital Management LP boosted its position in shares of Cullinan Therapeutics by 31.0% during the 3rd quarter. Lynx1 Capital Management LP now owns 5,766,090 shares of the company’s stock worth $34,193,000 after acquiring an additional 1,365,248 shares in the last quarter. Blue Owl Capital Holdings LP grew its position in shares of Cullinan Therapeutics by 5.2% during the third quarter. Blue Owl Capital Holdings LP now owns 2,510,972 shares of the company’s stock worth $14,890,000 after acquiring an additional 125,000 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Cullinan Therapeutics by 0.4% in the 2nd quarter. Franklin Resources Inc. now owns 2,228,160 shares of the company’s stock valued at $16,778,000 after acquiring an additional 8,399 shares during the period. State Street Corp raised its position in Cullinan Therapeutics by 31.0% in the 4th quarter. State Street Corp now owns 2,197,338 shares of the company’s stock valued at $22,742,000 after purchasing an additional 520,024 shares during the last quarter. Finally, Affinity Asset Advisors LLC raised its position in Cullinan Therapeutics by 632.4% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,932,106 shares of the company’s stock valued at $19,997,000 after purchasing an additional 1,668,289 shares during the last quarter. Hedge funds and other institutional investors own 86.31% of the company’s stock.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.